Innoviva (INVA) Stock Price, News & Analysis

Company Overview

Innoviva, Inc., incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches.

Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.

Key Stats

• Today's Range: $19.31 to $19.74
• 50-Day Range: $18.17 to $20.92
• 52-Week Range: $16.67 to $22.00
• Volume: 767,862 shs
• Average Volume: 641,134 shs
• Market Capitalization: $1.23 billion
• P/E Ratio: 63.07
• Dividend Yield: N/A
• Price Target: $42.75
• Consensus Rating: Buy

Innoviva Stock Analysis - MarketRank™

Innoviva scored higher than 97% of companies evaluated by MarketBeat, and ranked 46th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Innoviva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Innoviva has a consensus price target of $42.75, representing about 118.7% upside from its current price of $19.55.

Amount of Analyst Coverage

Innoviva has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 369.70%

Earnings Growth

Earnings for Innoviva are expected to grow by 369.70% in the coming year, from $0.33 to $1.55 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Innoviva is 63.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.20.

Price to Earnings Ratio vs. Sector

The P/E ratio of Innoviva is 63.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.13.

Price to Book Value per Share Ratio

Innoviva has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.80% of the float of Innoviva has been sold short.

Short Interest Ratio / Days to Cover

Innoviva has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Innoviva has recently decreased by 32.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innoviva does not currently pay a dividend.

Dividend Growth

Innoviva does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.33

Percentage of Shares Shorted

10.80% of the float of Innoviva has been sold short.

Short Interest Ratio / Days to Cover

Innoviva has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Innoviva has recently decreased by 32.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.29

News Sentiment

Innoviva has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Innoviva this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Innoviva to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innoviva insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.25% of the stock of Innoviva is held by insiders.

Percentage Held by Institutions

99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INVA Stock Analysis - Frequently Asked Questions

How have INVA shares performed this year?

Innoviva's stock was trading at $17.35 at the beginning of 2025. Since then, INVA stock has increased by 12.7% and is now trading at $19.55.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) released its earnings results on Wednesday, August, 6th. The biotechnology company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.20. The biotechnology company had revenue of $100.28 million for the quarter, compared to the consensus estimate of $87.10 million. Innoviva had a net margin of 10.44% and a trailing twelve-month return on equity of 18.67%.

Who are Innoviva's major shareholders?

Top institutional shareholders of Innoviva include Franklin Resources Inc. (4.50%), American Century Companies Inc. (3.29%), Systematic Financial Management LP (3.28%) and Arrowstreet Capital Limited Partnership (2.72%).
View institutional ownership trends.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INVA
• Previous Symbol: NASDAQ:THRX
• CIK: 1080014
• Web: www.inva.com
• Phone: (650) 238-9600
• Fax: 650-827-8690
• Employees: 100
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Innoviva: $42.75
• High Price Target: $55.00
• Low Price Target: $26.00
• Potential Upside/Downside: +118.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.31
• Trailing P/E Ratio: 63.07
• Forward P/E Ratio: 59.24
• P/E Growth: N/A
• Net Income: $23.39 million
• Net Margins: 10.44%
• Pretax Margin: 17.71%
• Return on Equity: 18.67%
• Return on Assets: 9.92%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 2.64
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $358.71 million
• Price / Sales: 3.43
• Cash Flow: $3.46 per share
• Price / Cash Flow: 5.65
• Book Value: $11.03 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 63,020,000
• Free Float: 61,603,000
• Market Cap: $1.23 billion
• Optionable: Optionable
• Beta: 0.47